Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY ACTIVATES NATIONWIDE DIRECT-TO-CONSUMER PEPTIDE SALES WITH RETAIL TELEHEALTH WEBSITE LAUNC

The Precision Peptide Company Inc. has launched its consumer-facing telehealth retail website, enabling consumers to purchase the company's peptide products on-line across the United States. The website is live. The new website serves as the consumer front end to the U.S. access pathway the company has assembled over recent months, designed to comply with applicable regulatory requirements, connecting customers with licensed provider networks, prescription workflows and U.S.-based pharmacy fulfilment. The launch builds on the prescription and telehealth infrastructure (see news release dated June 9, 2026) and the company's 503A sterile compounding agreement (see news release dated June 2, 2026), under which all of the company's peptides -- including BPC-157 -- will be 100 per cent compounded in the United States.

Supported by its recently announced LegitScript health care merchant certification (see news release dated June 23, 2026), the company is also positioned to process payments and market across major payment and advertising platforms, subject to each platform's applicable policies, as it scales its direct-to-consumer rollout.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "Launching our retail website is the moment all of this infrastructure comes together for the consumer. We have secured 100-per-cent U.S. compounding, put the prescription and telehealth pathway in place, and now we're opening the front door for customers. This is the start of our direct-to-consumer rollout, and it positions us to scale compliant, prescription-based access nationwide as regulatory clarity develops."

As previously disclosed, the Food and Drug Administration has referred several peptides (including BPC-157) to the Pharmacy Compounding Advisory Committee, which is scheduled to review these substances at a public meeting on July 23, 2026. With its U.S.-based 503A compounding agreement, prescription and telehealth infrastructure, and its consumer-facing retail website in place, the company has built and activated a pathway for prescription-based peptide access in advance of the review.

About The Precision Peptide Company Inc.

Precision Peptide is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.